Bonding Time In China: Multinationals Tap Closer R&D Ties With Domestics
This article was originally published in PharmAsia News
As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.
You may also be interested in...
Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.
The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.